# Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

> **NCT02778685** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole
- **DRUG:** Palbociclib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02778685
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-30
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-03-30
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778685, "Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02778685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*